Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Retina, Basic & Translational Research, Neuro-ophthalmology

Blanket Coverage

We are constantly learning more about genetic contributions to eye conditions – through both advancements in technology and work in the lab. But is the genetic information we uncover about diseases useful if many genes contribute to a single condition? Developing a therapeutic for one genetic contributor may help, but it may also result in a one-dimensional and potentially ineffective treatment for a disease that is multifaceted and multifactorial.

Researchers from Trinity School of Genetics and Microbiology in Dublin, Ireland, may have found a single gene target with a blanket coverage effect on treating impaired vision – and perhaps even blindness. The SARM1 gene has been shown to drive the process of retinal ganglion cell (RGC) degeneration of and ultimately causes visual impairment and blindness (1). Suppressing SARM1 in a mouse model protected spatial vision, increased RGC survival, and preserved axonal density in the optic nerves for four months. In essence, the group found that, by suppressing SARM1, they were able to combat mitochondrial dysfunction – a hallmark contributor to many ocular and neurodegenerative diseases – in the retina at a tissue level and at a functional level.

Although this research is promising, there is quite a way to go before therapeutics can be made available. Nonetheless, the work offers hope that we may one day be able to treat diseases that affect the optic nerve, such as glaucoma. Aside from the ocular applications, the positive effect of SARM1 suppression also stretches to neuronal cells (2) – meaning that the gene may be a viable target for neurodegenerative diseases, such as Alzheimer’s disease, that are characterized by mitochondrial dysfunction.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. LK Finnegan et al., Int J Mol Sci, 23, 1606 (2022). PMID: 35163535.
  2. GJ Farrar et al., Trends Genet, 29, 488 (2013). PMID: 23756086.
About the Author
Geoffrey Potjewyd

Associate Editor, The Ophthalmologist

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Here
Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register